AUTL logo

Autolus Therapeutics (AUTL) Company Overview

Profile

Full Name:

Autolus Therapeutics plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

June 22, 2018

Indexes:

Not included

Description:

Autolus Therapeutics is a biotechnology company focused on developing innovative cell therapies for cancer treatment. They create engineered T-cell therapies that target specific cancer cells, aiming to improve patient outcomes and provide new options for those with difficult-to-treat cancers.

Key Details

Price

$2.06

Annual Revenue

$1.70 M(-72.59% YoY)

Annual EPS

-$1.20(+23.57% YoY)

Annual ROE

-101.61%

Beta

1.38

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 13, 25 Needham
Buy
Dec 9, 24 Needham
Buy
Dec 5, 24 Needham
Buy
Nov 18, 24 Goldman Sachs
Buy
Nov 15, 24 Redburn Atlantic
Buy
Nov 13, 24 Needham
Buy
Nov 12, 24 Needham
Buy
Nov 11, 24 Needham
Buy
Jun 17, 24 Needham
Buy
Jun 3, 24 Needham
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
AUTL
globenewswire.comJanuary 17, 2025

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai'i Convention Center, Honolulu, HI. “Building on our data presented at ASH in December, we come to Tandem with an updated health economic cost model directly comparing the cost of adverse events of AUCATZYL® versus other CAR-T cell therapies, which demonstrates that the shorter duration and lower incidence of CRS and ICANS contributes to a reduction in healthcare costs,” said Dr. Christian Itin, Chief Executive Officer of Autolus.

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
AUTL
seekingalpha.comNovember 12, 2024

Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Olivia Manser - Director-Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Conference Call Participants James Shin - Deutsche Bank Matthew Phipps - William Blair Sebastiaan van der Schoot - VLK Hanze Zu - Jefferies Gil Blum - Needham & Company Jacob Mekhael - KBC Securities Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Third Quarter 2024 Financial Results and Business Updates. At this time, all participants are in a listen-only mode.

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
AUTL
globenewswire.comNovember 8, 2024

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy) Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the U.S. Food and Drug Administration (FDA) has granted marketing approval for AUCATZYL® (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). “Adult ALL is an extremely aggressive cancer, and there is a high unmet medical need that exists in the treatment of patients with this disease once they relapse, where historically they suffer from poor outcomes,” said Elias Jabbour, MD, U.S. lead investigator of the FELIX study and professor of Leukemia, ALL Section Chief, at The University of Texas MD Anderson Cancer Center, Houston, Texas.

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
AUTL
globenewswire.comOctober 28, 2024

LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update.

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
AUTL
seekingalpha.comSeptember 6, 2024

Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights.

Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript
AUTL
seekingalpha.comAugust 10, 2024

Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Olivia Manser – Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Asthika Goonewardene – Truist Kelly Shi – Jefferies James Shin – Deutsche Bank Matthew Phipps – William Blair Yanan Zhu – Wells Fargo Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Second Quarter 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded.

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
AUTL
globenewswire.comJuly 26, 2024

LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights before open of US markets on Thursday, August 8, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update.

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
AUTL
globenewswire.comMay 31, 2024

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated with improved event-free survival Autolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below) LONDON, May 31, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces longer-term follow-up and additional data analysis from the pivotal Phase 1b/2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago). “At 21 months of median follow up, we're really pleased to be observing the potential for a long-term plateau of survival outcomes with obe-cel in the FELIX trial,” said Dr. Christian Itin, Chief Executive Officer of Autolus.

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
AUTL
globenewswire.comMay 17, 2024

Autolus Therapeutics plc will be presenting additional analyses from the FELIX Phase 2 data at upcoming conferences, with two patients enrolled in the Phase 1 SLE trial. The company is on track to release initial data by the end of 2024. The European Medicines Agency has accepted the Market Authorization Application for obe-cel in r/r adult ALL. A conference call will be held today at 08:30 am EDT/13:30 pm BST, and participants should pre-register using the link provided in the press release. Autolus CEO, Dr. Christian Itin, stated that the company is actively engaging with the FDA in the regulatory review process for obe-cel and preparing for commercial readiness activities.

Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
AUTL
seekingalpha.comMay 17, 2024

Autolus Therapeutics plc (NASDAQ:AUTL) is holding a conference call on May 17, 2024 at 8:30 AM ET to discuss its Q1 2024 earnings and business updates. The call will be led by CEO Christian Itin and CFO Rob Dolski, with investor relations represented by Olivia Manser. Various analysts from firms such as Jefferies, Deutsche Bank, and Needham & Company will also be participating in the call. The call is being recorded for reference.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Autolus Therapeutics?
  • Does Autolus Therapeutics pay dividends?
  • What sector is Autolus Therapeutics in?
  • What industry is Autolus Therapeutics in?
  • What country is Autolus Therapeutics based in?
  • When did Autolus Therapeutics go public?
  • Is Autolus Therapeutics in the S&P 500?
  • Is Autolus Therapeutics in the NASDAQ 100?
  • Is Autolus Therapeutics in the Dow Jones?
  • When was Autolus Therapeutics's last earnings report?
  • When does Autolus Therapeutics report earnings?
  • Should I buy Autolus Therapeutics stock now?

What is the ticker symbol for Autolus Therapeutics?

The ticker symbol for Autolus Therapeutics is NASDAQ:AUTL

Does Autolus Therapeutics pay dividends?

No, Autolus Therapeutics does not pay dividends

What sector is Autolus Therapeutics in?

Autolus Therapeutics is in the Healthcare sector

What industry is Autolus Therapeutics in?

Autolus Therapeutics is in the Biotechnology industry

What country is Autolus Therapeutics based in?

Autolus Therapeutics is headquartered in United Kingdom

When did Autolus Therapeutics go public?

Autolus Therapeutics's initial public offering (IPO) was on June 22, 2018

Is Autolus Therapeutics in the S&P 500?

No, Autolus Therapeutics is not included in the S&P 500 index

Is Autolus Therapeutics in the NASDAQ 100?

No, Autolus Therapeutics is not included in the NASDAQ 100 index

Is Autolus Therapeutics in the Dow Jones?

No, Autolus Therapeutics is not included in the Dow Jones index

When was Autolus Therapeutics's last earnings report?

Autolus Therapeutics's most recent earnings report was on Nov 12, 2024

When does Autolus Therapeutics report earnings?

The next expected earnings date for Autolus Therapeutics is Mar 14, 2025

Should I buy Autolus Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions